SG11201808552XA - T-cell modulatory multimeric polypeptides and methods of use thereof - Google Patents

T-cell modulatory multimeric polypeptides and methods of use thereof

Info

Publication number
SG11201808552XA
SG11201808552XA SG11201808552XA SG11201808552XA SG11201808552XA SG 11201808552X A SG11201808552X A SG 11201808552XA SG 11201808552X A SG11201808552X A SG 11201808552XA SG 11201808552X A SG11201808552X A SG 11201808552XA SG 11201808552X A SG11201808552X A SG 11201808552XA
Authority
SG
Singapore
Prior art keywords
international
cell modulatory
cell
present disclosure
modulatory multimeric
Prior art date
Application number
SG11201808552XA
Inventor
Iii Ronald D Seidel
Rodolfo Chaparro
Original Assignee
Cue Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cue Biopharma Inc filed Critical Cue Biopharma Inc
Publication of SG11201808552XA publication Critical patent/SG11201808552XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111 0111011110111110101111111 011111111111011 1 111111101110 III 1111 III1 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/201210 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: (74) Agent: BORDEN, Paula A.; 201 Redwood Shores Park- A61K 39/395 (2006.01) CO7K 14/47 (2006.01) way, Suite 200, Redwood City, California 94065 (US). A61K 48/00 (2006.01) Cl 2N 15/63 (2006.01) CO7K 14/00 (2006.01) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, PCT/US2017/033187 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (22) International Filing Date: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 17 May 2017 (17.05.2017) HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (25) Filing Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (26) Publication Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (30) Priority Data: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 62/338,410 18 May 2016 (18.05.2016) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: CUE BIOPHARMA, INC. [US/US]; 675 kind of regional protection available): ARIPO (BW, GH, West Kendall Street, Cambridge, Massachusetts 02142 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (US). UG, TM), ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventors: SEIDEL III, Ronald D.; 675 West Kendall EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — ge,ass Street, Cambridge, Massachusetts 02142 (US). CHAPAR- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, RO, Rodolfo; 675 West Kendall Street, Cambridge, Mass- achusetts 02142 (US). = Title: T-CELL MODULATORY MULTIMERIC POLYPEPTIDES AND (54) METHODS OF USE THEREOF = T Cell Modulatory = Domain Targeting Epitope = = = = = = = — _ C it = B2M = = = = T Cell Modulatory Domain — 1-1 Fc FIG. IC 0 1-1 ei 1-1 (57) : The present disclosure provides T-cell modulatory multimeric polypeptides comprising two different immunomodula- 0 el tory polypeptides, at least one of which is a variant immunomodulatory polypeptide. The present disclosure provides nucleic acids ----- comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. IN ,-1 The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T- 0 cell modulatory multimeric polypeptide of the present disclosure. ei C [Continued on next page] WO 2017/201210 Al MIDEDIMOMMIDIROFIEHIMIIMIHOMERVOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt amendments (Rule 48.2(h)) of — with sequence listing part of description (Rule 5.2(a))
SG11201808552XA 2016-05-18 2017-05-17 T-cell modulatory multimeric polypeptides and methods of use thereof SG11201808552XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338410P 2016-05-18 2016-05-18
PCT/US2017/033187 WO2017201210A1 (en) 2016-05-18 2017-05-17 T-cell modulatory multimeric polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201808552XA true SG11201808552XA (en) 2018-10-30

Family

ID=60326131

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808552XA SG11201808552XA (en) 2016-05-18 2017-05-17 T-cell modulatory multimeric polypeptides and methods of use thereof

Country Status (11)

Country Link
US (2) US11505591B2 (en)
EP (1) EP3458096A4 (en)
JP (1) JP7071288B2 (en)
KR (1) KR20190019068A (en)
CN (1) CN109475628A (en)
AU (1) AU2017268348A1 (en)
BR (1) BR112018073606A2 (en)
CA (1) CA3019005A1 (en)
IL (1) IL262403A (en)
SG (1) SG11201808552XA (en)
WO (1) WO2017201210A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4270006A3 (en) 2014-06-13 2024-01-10 Immudex ApS General detection and isolation of specific cells by binding of labeled molecules
TW201722985A (en) 2015-11-02 2017-07-01 戊瑞治療有限公司 CD80 extracellular domain polypeptides and their use in cancer treatment
SG11201808783XA (en) 2016-04-15 2018-11-29 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
KR20190019068A (en) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-cell modulated multimeric polypeptides and methods for their use
IL303806B1 (en) 2016-12-22 2024-01-01 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2018234628B2 (en) * 2017-03-15 2023-07-20 Cue Biopharma, Inc. Methods for modulating an immune response
AU2018235838B2 (en) 2017-03-16 2023-12-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
MX2019012849A (en) 2017-04-28 2019-11-28 Five Prime Therapeutics Inc Methods of treatment with cd80 extracellular domain polypeptides.
AU2018327224A1 (en) * 2017-09-07 2020-04-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
CN109879969B (en) * 2017-12-06 2024-04-09 天士力生物医药股份有限公司 HM-3 fusion protein and application thereof
WO2019139896A1 (en) * 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
TW202039542A (en) * 2018-12-19 2020-11-01 美商庫爾生物製藥有限公司 Multimeric t-cell modulatory polypeptides and methods of use thereof
KR20210104700A (en) * 2018-12-19 2021-08-25 큐 바이오파마, 인크. Multimeric T-cell regulatory polypeptides and methods of use thereof
WO2020132136A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020132135A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020181273A1 (en) * 2019-03-06 2020-09-10 Cue Biopharma, Inc. Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
CN113795502A (en) * 2019-04-26 2021-12-14 轩竹生物科技有限公司 CD80 variant protein and application thereof
MX2021014476A (en) * 2019-05-29 2022-02-11 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof.
JP2022536581A (en) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド Multimeric T cell regulatory polypeptides and methods of use thereof
CA3146591A1 (en) * 2019-09-20 2021-03-25 Ronald D. Seidel Iii T-cell modulatory polypeptides and methods of use thereof
AU2021272895A1 (en) 2020-05-12 2022-09-22 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
ES2249761T3 (en) 1993-06-24 2006-04-01 Advec Inc. ADENOVIRUS VECTORS FOR GENE THERAPY.
EP2113569A1 (en) 1993-10-25 2009-11-04 CANJI, Inc. Recombinant adenoviral vector and methods of use
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6211342B1 (en) 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
WO1998035981A1 (en) 1997-02-13 1998-08-20 The Regents Of The University Of California Prevention and treatment of hepatocellular cancer
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US20030007978A1 (en) 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6696304B1 (en) 1999-02-24 2004-02-24 Luminex Corporation Particulate solid phase immobilized protein quantitation
IL145795A0 (en) * 1999-04-30 2002-07-25 Univ Pennsylvania Mutant human cd80 and compositions for and methods of making and using the same
US20020006664A1 (en) 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
EP1287363A2 (en) 2000-05-25 2003-03-05 Sunol Molecular Corporation Modulation of t-cell receptor interactions
US20020122820A1 (en) 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
US6800748B2 (en) 2001-01-25 2004-10-05 Large Scale Biology Corporation Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector
WO2002072631A2 (en) 2001-03-14 2002-09-19 Dakocytomation Denmark A/S Mhc molecule constructs and their usesfor diagnosis and therapy
WO2002093129A2 (en) 2001-05-15 2002-11-21 University Of Medicine & Dentistry Of New Jersey Methods for analyzing interactions between proteins in live and intact cells
CA2463310A1 (en) 2001-06-04 2002-12-12 Ml Laboratories Plc Compositions and methods for high-level, large-scale production of recombinant proteins
US20030017134A1 (en) 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AU2002368044A1 (en) * 2001-06-22 2004-04-19 Maxygen, Inc. Co-stimulatory molecules
AU2002322211A1 (en) 2001-07-12 2003-01-29 Canvac Methods and compisitions for activation human t cells in vitro
AU2002363354A1 (en) 2001-07-27 2003-05-19 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
RU2312677C9 (en) 2001-12-04 2008-03-27 Мерк Патент Гмбх Immunocytokines possessing modulated selectivity
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7432351B1 (en) * 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
EP1599502A1 (en) 2003-02-27 2005-11-30 TheraVision GmbH A molecule which binds cd80 and cd86
AU2003901876A0 (en) 2003-04-17 2003-05-08 The Macfarlane Burnet Institute For Medical Research And Public Health Viral vector
US20050042641A1 (en) 2003-05-27 2005-02-24 Cold Spring Harbor Laboratory In vivo high throughput selection of RNAi probes
ES2559409T3 (en) 2003-09-05 2016-02-12 Oregon Health & Science University Monomeric recombinant MHC molecules useful for the manipulation of antigen-specific T cells
US7470513B2 (en) 2003-11-10 2008-12-30 Academia Sinica Risk assessment for adverse drug reactions
JP2007527242A (en) 2004-03-05 2007-09-27 カイロン コーポレーション In vitro test system for predicting patient tolerance of therapeutic agents
DE102004014983A1 (en) 2004-03-26 2005-10-20 Univ Stuttgart Recombinant polypeptides of the members of the TNF ligand family and their use
EP1773383B1 (en) 2004-05-27 2012-09-12 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20070166788A1 (en) 2005-11-10 2007-07-19 Pei Jin Methods for production of receptor and ligand isoforms
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc Genetic packages and uses thereof
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
MX2008014722A (en) 2006-05-19 2011-04-15 Teva Pharma Fusion proteins, uses thereof and processes for producing same.
EP1889851A1 (en) 2006-08-18 2008-02-20 Charite Universitätsmedizin-Berlin PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
US8992937B2 (en) 2006-08-28 2015-03-31 Washington University Disulfide trap MHC class I molecules and uses therefor
SI2341142T1 (en) 2006-12-28 2015-03-31 International Institute Of Cancer Immunology, Inc. HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising same
CN103736086A (en) 2007-02-15 2014-04-23 曼康公司 A method for enhancing t cell response
WO2008113970A2 (en) 2007-03-16 2008-09-25 Ucl Business Plc Peptides
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN103298935A (en) 2007-08-15 2013-09-11 阿穆尼克斯公司 Compositions and methods for modifying properties of biologically active polypeptides
US8926961B2 (en) 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
CN101418309B (en) 2007-10-23 2011-05-04 中国农业科学院上海兽医研究所 Cloning, expression and application of eimeria tenella protein disulfide isomerase gene
DE102008023820A1 (en) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
EP2184070A1 (en) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G proteins and pharmaceutical uses thereof
US20110274650A1 (en) 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
CA2764649C (en) 2009-06-25 2019-02-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
SI3279215T1 (en) 2009-11-24 2020-07-31 Medimmune Limited Targeted binding agents against b7-h1
EP3327040B1 (en) 2010-09-21 2021-06-23 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
SG195077A1 (en) 2011-06-22 2013-12-30 Hoffmann La Roche Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
ES2810424T3 (en) 2011-06-30 2021-03-08 Genzyme Corp T cell activation inhibitors
WO2013030620A2 (en) 2011-08-30 2013-03-07 Jacobs University Bremen Ggmbh Gene encoded for an mhc class i molecule, plasmid, expression system protein, multimer, reagent and kit for analyzing a t cell frequency
US8956619B2 (en) 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
WO2013079174A1 (en) 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
WO2013116656A1 (en) 2012-02-03 2013-08-08 Emory University Immunostimulatory compositions, particles, and uses related thereto
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
JP2015537043A (en) 2012-11-30 2015-12-24 ロシュ グリクアート アーゲー Removal of cancer cells by circulating virus-specific cytotoxic T cells using MHC class I targeting cancer cells containing multifunctional proteins
KR102208505B1 (en) 2012-12-11 2021-01-27 앨버트 아인슈타인 컬리지 오브 메디신 Methods for high throughput receptor:ligand identification
KR20150097688A (en) 2012-12-21 2015-08-26 에프. 호프만-라 로슈 아게 Disulfide-linked multivalent mhc class i comprising multi-function proteins
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
TWI666026B (en) 2013-03-29 2019-07-21 日商大日本住友製藥股份有限公司 WT1 antigen peptide-binding vaccine
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
CN105492017B (en) 2013-07-19 2020-12-01 弗拉芒区生物技术研究所 Targeting modified TNF family members
KR102488477B1 (en) 2014-01-21 2023-01-13 앨버트 아인슈타인 컬리지 오브 메디신 Cellular platform for rapid and comprehensive t-cell immunomonitoring
WO2015130766A1 (en) 2014-02-25 2015-09-03 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
WO2015129790A1 (en) 2014-02-26 2015-09-03 株式会社バイオイミュランス Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
AU2015277460B2 (en) * 2014-06-18 2020-10-08 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
TWI726608B (en) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
DK3172227T3 (en) 2014-07-21 2019-12-02 Delinia Inc Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
US10166273B2 (en) 2014-08-12 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein
JP2017525370A (en) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing and using tumor necrosis factor superfamily and TNF-like ligand muteins
BR112016030670A2 (en) 2014-08-29 2017-10-31 Hoffmann La Roche "immunocytokine"
SG10201908203SA (en) 2015-03-05 2019-10-30 Hutchinson Fred Cancer Res Immunomodulatory Fusion Proteins And Uses Thereof
CN114773486A (en) 2015-04-17 2022-07-22 高山免疫科学股份有限公司 Immunomodulatory proteins with tunable affinity
WO2017008844A1 (en) 2015-07-14 2017-01-19 Biontech Ag Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
CA2993429A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
CN106565836B (en) 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 High affinity soluble PDL-1 molecules
JP6991969B2 (en) 2015-11-20 2022-03-03 メモリアル スローン ケタリング キャンサー センター Methods and compositions for treating cancer
IL260296B2 (en) 2016-01-04 2024-01-01 Cour Pharmaceuticals Dev Company Inc Particles encapsulating fusion proteins containing linked epitopes
WO2017151818A2 (en) 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP7372036B2 (en) * 2016-03-03 2023-10-31 キュー バイオファーマ， インコーポレイテッド T cell regulatory multimeric polypeptides and methods of use thereof
CN115073581A (en) 2016-05-04 2022-09-20 美国安进公司 Interleukin-2 muteins for expansion of T regulatory cells
KR20190019068A (en) 2016-05-18 2019-02-26 큐 바이오파마, 인크. T-cell modulated multimeric polypeptides and methods for their use
CN109689096A (en) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 Variant PD-L1 polypeptide, T cell modulability multimeric polypeptide and its application method
IL303806B1 (en) 2016-12-22 2024-01-01 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018129474A1 (en) * 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2018234628B2 (en) 2017-03-15 2023-07-20 Cue Biopharma, Inc. Methods for modulating an immune response
JP2021500855A (en) * 2017-09-07 2021-01-14 キュー バイオファーマ， インコーポレイテッド Antigen-presenting polypeptides and how to use them
IL297361B1 (en) * 2017-09-07 2024-03-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof
AU2018327224A1 (en) * 2017-09-07 2020-04-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
TW201925235A (en) * 2017-09-07 2019-07-01 美商信號生物製藥公司 Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof
WO2019139896A1 (en) * 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2020132136A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN113823723A (en) 2020-06-18 2021-12-21 光宝光电(常州)有限公司 Light emitting diode packaging structure

Also Published As

Publication number Publication date
EP3458096A1 (en) 2019-03-27
JP2019522465A (en) 2019-08-15
AU2017268348A1 (en) 2018-10-25
US20230279075A1 (en) 2023-09-07
EP3458096A4 (en) 2019-11-27
US11505591B2 (en) 2022-11-22
KR20190019068A (en) 2019-02-26
IL262403A (en) 2018-12-31
CN109475628A (en) 2019-03-15
BR112018073606A2 (en) 2019-02-26
WO2017201210A1 (en) 2017-11-23
CA3019005A1 (en) 2017-11-23
JP7071288B2 (en) 2022-05-18
US20190106476A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
SG11201808552XA (en) T-cell modulatory multimeric polypeptides and methods of use thereof
SG11201908391XA (en) Methods for modulating an immune response
SG11201901528RA (en) Proteolytically cleavable chimeric polypeptides and methods of use thereof
SG11201809709UA (en) Aerosol generating systems
SG11201910101SA (en) Alphavirus neoantigen vectors
SG11201807286WA (en) Methods and compositions for transducing lymphocytes and regulated expansion thereof
SG11201809522WA (en) Method of nucleic acid sequence determination
SG11201808990QA (en) Compositions for topical application of compounds
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201810179RA (en) Novel crispr enzymes and systems
SG11201909949XA (en) Targeted immunotolerance
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201806650VA (en) Systems and methods for providing a personal distributed ledger
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201407505XA (en) Aptamer-based multiplexed assays
SG11201804721SA (en) Modulators of complement activity
SG11201807134RA (en) Transposon system and methods of use
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201808152PA (en) Dna antibody constructs and method of using same
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201901684XA (en) Anti-dengue virus antibodies, polypeptides containing variant fc regions, and methods of use